ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Sunday, November 13, 2022

9:00AM-10:30AM: Abstract Number: 0754

Persistent but Disturbed Germinal Center Reaction Among 3rd SARS-CoV-2 Vaccination After Rituximab Exposure

Immunological Complications of Medical Therapy Poster

9:00AM-10:30AM: Abstract Number: 0649

Phosphofructokinase P Fine-Tunes T Regulatory Cell Metabolism, Function and Stability in Systemic Autoimmunity

SLE – Etiology and Pathogenesis Poster

9:00AM-10:30AM: Abstract Number: 0939

Pilot Study: A Novel Method for Cervical Health Monitoring in African American Women with Systemic Lupus Erythematosus (SLE) Using a Self- Sampling Brush to Assess Cervical HPV Infection and Cervical Cytology

Reproductive Issues in Rheumatic Disorders Poster

9:00AM-10:30AM: Abstract Number: 0903

Plasma Inflammatory Protein Biomarkers May Predict Cardiovascular Events in Early Rheumatoid Arthritis

RA – Diagnosis, Manifestations, and Outcomes Poster II

9:00AM-10:30AM: Abstract Number: 0709

Population Based Prevalence and Incidence of Mixed Connective Tissue Disease from the Manhattan Lupus Surveillance Program

Epidemiology and Public Health Poster I

9:00AM-10:30AM: Abstract Number: 0795

Post-Acute COVID-19 Sequalae (PACS) with New-onset Rheumatological Complications

Infection-related Rheumatic Disease Poster

9:00AM-10:30AM: Abstract Number: 0792

Post-mRNA Vaccine Flares in Autoimmune Inflammatory Rheumatic Diseases: Results from the COronavirus National Vaccine Registry for ImmuNe Diseases SINGapore (CONVIN-SING)

Infection-related Rheumatic Disease Poster

9:00AM-10:30AM: Abstract Number: 0614

Post-translationally Modified Fibrinogen Activated Macrophages Drive the Expression of Fibrotic Genes in Rheumatoid Arthritis Fibroblast-Like Synoviocytes

RA – Etiology and Pathogenesis Poster

9:00AM-10:30AM: Abstract Number: 0848

Postoperative Flares and Peri-arthroscopic Management of Immunosuppressive Medications in Patients with Rheumatic Disease

Orthopedics, Low Back Pain, and Rehabilitation Poster

9:00AM-10:30AM: Abstract Number: 0840

Postoperative Risk of Immunosuppression in Rheumatic Disease Patients Undergoing Arthroscopy

Orthopedics, Low Back Pain, and Rehabilitation Poster

9:00AM-10:30AM: Abstract Number: 0716

Posttraumatic Stress Disorder Symptoms in Systemic Autoimmune Rheumatic Disease Patients During the Early COVID-19 Pandemic

Epidemiology and Public Health Poster I

9:00AM-10:30AM: Abstract Number: 0905

Predicting Disease Activity in Rheumatoid Arthritis Patients Using Machine Learning: Data from the ACR’s RISE Registry

RA – Diagnosis, Manifestations, and Outcomes Poster II

9:00AM-10:30AM: Abstract Number: 0825

Predicting Outcomes in Macrophage Activation Syndrome (MAS): A Retrospective Study on 43 Consecutive Patients with MAS

Miscellaneous Rheumatic and Inflammatory Diseases Poster II

9:00AM-10:30AM: Abstract Number: 0858

Predicting the Occurrence of Drug-Free Inactive Disease Two Years After Diagnosis of Non-Systemic Juvenile Idiopathic Arthritis

Pediatric Rheumatology – Clinical Poster I: JIA

9:00AM-10:30AM: Abstract Number: 0892

Predicting Value of Circulating Semaphorin 4A for Rheumatoid Arthritis Progression and Response to Treatment

RA – Diagnosis, Manifestations, and Outcomes Poster II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].